Angius, Gesuino <br/><br/>
Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  01 2020 
 - 9-20 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1432-0843 
<br/><br/><label>Standard No.: </label>10.1007/s00280-019-03950-y  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Checkpoint Kinase 1--antagonists & inhibitors<br/>Checkpoint Kinase 2--antagonists & inhibitors<br/>Clinical Trials as Topic<br/>Drug Evaluation, Preclinical<br/>Humans<br/>Neoplasms--drug therapy<br/>Protein Kinase Inhibitors--therapeutic use<br/>Pyrazines--therapeutic use<br/>Pyrazoles--therapeutic use